Jagsonpal Pharmaceuticals Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.5K Cr
Jagsonpal aims for mid-to-high teen growth in revenue, targeting to outgrow the Indian pharma market by 1.5x. Jagsonpal Pharmaceuticals targets mid-to-high teen revenue growth, aiming to outgrow the Indian pharma industry by 1.5x.
From Jagsonpal Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹238
Market Cap
₹1.5K Cr
P/E Ratio
31.8
Revenue Rank
Margin Rank
How does Jagsonpal Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Jagsonpal Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹64 Cr, net profit ₹9 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3📈 Profitability & Margins
Rank 1- →Jagsonpal Pharmaceuticals targets mid-to-high teen revenue growth, aiming to outgrow the Indian pharma industry by 1.5x.
- →The company expects continued productivity improvements and product mix enhancement to increase gross margins over time.
- →With the acquisition of Aequitas Healthcare, JPL targets Rs.10 crores EBITDA from this business by FY28-'29, up from Rs.50 lakhs in FY26.
- →Aequitas is expected to scale to Rs.100 crores revenue within 2.5 years, supporting margin expansion through innovation and premium product introductions.
- →Overall operating EBITDA grew 21% YoY in Q1 FY27; PAT increased 22%, with margin expansions of 240 bps and 176 bps respectively.
- →Strong cash flow and disciplined capital allocation are expected to sustain and enhance return ratios.
- →Incremental EBITDA growth will come from both organic growth of key brands like Indocap, Maintane, Endoreg, and inorganic growth through hospital segment integration with Aequitas.
🏗️ Capital Expenditure Plans
Yes- →Jagsonpal Pharmaceuticals has been focusing on disciplined capital allocation balancing organic and inorganic growth.
- →Over the last four years, the company generated over Rs.250 crores of operating cash used for strategic acquisitions like Yash Pharma (over Rs.90 crores).
- →Recently acquired 85% stake in Aequitas Healthcare for Rs.20.8 crores to enter and expand in the hospital segment.
- →Integration planning for Aequitas underway with expected synergies over the next 36 months.
- →The company continues to evaluate value-accretive inorganic opportunities for growth.
- →No specific mention of new or upcoming capital expenditure projects beyond acquisitions and integration efforts within the transcript.
- →Emphasis is on leveraging acquisitions like Aequitas and boosting organic growth to drive future value creation rather than major new capex projects.
💰 Fundraising & Capital Structure
No information- →The transcript on page 17 does not mention any current or planned fundraising through debt or equity.
- →There is no indication of new debt issuance or equity offerings discussed in the Q&A or management comments.
- →The company completed a significant Rs.40 crores share buyback, demonstrating a focus on returning capital to shareholders rather than raising new equity.
- →Discussions primarily focus on organic growth, operational improvements, and integration of the Aequitas acquisition.
- →No explicit comments or plans about future fundraising activities are mentioned in the provided pages.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q1 FY27 results?
Jagsonpal aims for mid-to-high teen growth in revenue, targeting to outgrow the Indian pharma market by 1.5x. Jagsonpal Pharmaceuticals targets mid-to-high teen revenue growth, aiming to outgrow the Indian pharma industry by 1.5x.
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
Jagsonpal Pharmaceuticals has been focusing on disciplined capital allocation balancing organic and inorganic growth.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.